

Prolaris[®]

Prostate Cancer Prognostic Test



The intermediate-risk prostate cancer path isn't always clear. Let the Prolaris Test light the way.


The Prolaris Prostate Cancer Prognostic Test delivers a personalized risk assessment of localized prostate cancer, helping you identify which patients may be appropriate to pursue active surveillance (AS) and who may need definitive treatment.

- Improves risk stratification by assessing tumor biology through Cell Cycle Proliferation (CCP), which has been shown to be more prognostic over clinical features^{1,3}
- Uniquely provides two clinically validated thresholds: one for identifying patients suitable for active surveillance, and another for guiding single-modal and multi-modal therapy decisions^{4,5}
- Only test with an active surveillance threshold validated in untreated patients, making it uniquely suited to guide initial treatment decisions⁴



The Prolaris Test outperforms all other biomarkers in active surveillance⁶


Choose the clarity that only the Prolaris Test provides



A comprehensive score to more accurately determine cancer aggressiveness

The Prolaris Test combines a validated molecular score measuring the expression of 31 CCP genes with clinical-pathological features.

The Prolaris CCP score is the **most accurate measure of cancer aggressiveness** and was shown to be **twice as predictive of 10-year disease-specific mortality** compared to clinical variables alone.¹⁻³



High actionability means real-life impact⁶

65%

of patients who received the Prolaris Test had changes to their medical management^{8,9}

2x

more patients choose AS when the Prolaris test recommends it compared to definitive treatment¹⁰

At 3 years,

patients identified by Prolaris as suitable for active surveillance were 1.5 times more likely to remain on active surveillance¹⁰

Myriad Oncology provides clinical utility across the prostate cancer care continuum

| | | | |
|--|---|--|--------------------|
| | Early-Stage & Treatment Selection | Late-Stage Disease | Progression |
| | <ul style="list-style-type: none"> Active surveillance Surgery Radiation therapy Adjuvant therapy | <ul style="list-style-type: none"> Targeted therapy selection Clinical trial eligibility | |
| | | | |



LEARN MORE
myriad.com/urology

Germline

MyRisk[®]
Hereditary Cancer Test

Tumor Genomic

Precise Tumor[®]
Molecular Profile Test

Prolaris[®]
Prostate Cancer Prognostic Test

MyChoice[®] CDx
Myriad HRD Companion Diagnostic Test

EndoPredict[®]
Breast Cancer Prognostic Test

References: **1.** Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. *Lancet Oncol.* 2011;12(3):245-255. **2.** Cuzick J, Berney DM, Fisher G, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. *Br J Cancer.* 2012;106(6):1095-1099. **3.** Cuzick J, Stone S, Fisher G, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. *Br J Cancer.* 2015;113(3):382-389. **4.** Lin DW, Crawford ED, Keane T, et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. *Urol Oncol.* 2018;36(6):310.e7-310.e13. **5.** Tward JD, Schlomm T, Bardot S, et al. Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy. *Clin Genitourin Cancer.* 2021;19(4):296-304.e3. **6.** Hu JC, Tosoian JJ, Qi J, et al. Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. *JCO Precis Oncol.* 2018;2:P0.18.00163. **7.** Tward J, Lenz L, Flake DD II, et al. The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. *Int J Radiat Oncol Biol Phys.* 2022;113(1):66-76. **8.** Shore ND, Kella N, Moran B, et al. Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. *J Urol.* 2016;195(3):612-618. **9.** Crawford ED, Scholz MC, Kar AJ, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. *Curr Med Res Opin.* 2014;30(6):1025-1031. **10.** Lenz L, Clegg W, Iliev D, et al. Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing. *Prostate Cancer Prostatic Dis.* 2025;28(2):427-434.